Wexford Capital’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

Wexford Capital’s Portfolio EIDX Stock Details EIDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-10,000	Closed	-$574K	–	176
2019 Q4	$574K	Sell	10,000 -10,000	-50%	-$495K	0.09%	101
2019 Q3	$719K	Sell	20,000 -10,000	-33%	-$391K	0.1%	86
2019 Q2	$932K	Sell	30,000 -10,000	-25%	-$271K	0.11%	88
2019 Q1	$938K	Hold	40,000	–	–	0.08%	71
2018 Q4	$550K	Buy	40,000 +20,000	+100%	+$252K	0.05%	66
2018 Q3	$200K	Buy	+20,000	New	+$329K	0.01%	135

Other funds holding EIDX

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Wexford Capital's EIDX Position: Q1 2020 in Review

Wexford Capital sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q1 2020, closing a stake of 10,000 shares — an estimated $574K sold.

Wexford Capital first reported a position in EIDX in Q3 2018 and held it in 6 quarters. The position peaked at $938K in Q1 2019. 89 funds tracked by Wall St. Rank hold EIDX as of Q1 2020.

Wexford Capital reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
Wexford Capital sold 10,000 Eidos Therapeutics, Inc. Common Stock shares in Q1 2020, an estimated $574K.
Wexford Capital first reported a position in Eidos Therapeutics, Inc. Common Stock in Q3 2018 and held it in 6 quarters.
Wexford Capital's Eidos Therapeutics, Inc. Common Stock position peaked at $938K in Q1 2019.
89 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q1 2020.

Based on Wexford Capital's 13F filing for Q1 2020, filed 18 May 2020.